§
Luxuse
Patent Intelligence
Sign In
Patent US5667764A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5667764A Expired / Lapsed US ⏱️ 0.0 years remaining

Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles

Assignee: Zynaxis Technologies Inc
•
Filing: 1992-05-15
•
Granted: 1997-09-16
•
Expires: 2012-05-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds are provided having the capability of binding therapeutically active substances to lipid containing bio-compatible particles, such as cells or viruses. These compounds include a bio-affecting moiety, comprising a therapeutically active substance, which is linked via a linking moiety to at least one hydrocarbon substituent selected so that the compounds is sufficiently non-polar to impart lipid binding capability to the compound. Thus, compounds of the invention are useful for site-selective delivery of therapeutic agents, and retention thereof at the selected site. Methods are provided for using various compounds of the invention in treatment of diseases or other pathological conditions. For example, methods are provided for treatment of: (1) post-angioplasty restenosis; (2) rheumatoid arthritis; (3) tumor cell proliferation, particularly tumor cells associated with ovarian cancer; and (4) psoriasis.

Inventors

  • 👤 Gregory A. Kopia
  • 👤 Paul K. Horan
  • 👤 Brian D. Gray
  • 👤 David E. Troutner
  • 👤 Katharine A. Muirhead
  • 👤 Kamleshkumar A. Sheth
  • 👤 Chia-En Lin
  • 👤 Zhizhou Yu
  • 👤 Bruce D. Jensen
  • 👤 Sue Ellen Slezak

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 14:12
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/04; C07D209/08; A; A61; A61K; A61K41/00; A61K41/0085; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/60; A61K47/69; A61K47/6901; A61K49/00; A61K49/0002; A61K49/001; A61K49/0013; A61K49/0017; A61K49/0019; A61K49/0021; A61K49/0026; A61K49/0032; A61K49/005; A61K49/0052; A61K49/06; A61K49/18; A61K49/1896; A61K51/00; A61K51/02; A61K51/04; A61K51/0497; A61K51/12; A61K51/1258; A61P; A61P31/00; A61P35/00; C07C; C07C229/00; C07C229/02; C07C229/04; C07C229/06; C07C229/10; C07C229/16; C07D219/00; C07D219/04; C07D219/08; C07D263/00; C07D263/52; C07D263/62; C08; C08B; C08B37/00; C08B37/006; C08B37/0063; C08B37/0075; A61K2121/00; A61K2123/00

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 384 words
A compound having the formula: wherein B represents a chemotherapeutic substance; R and R 1 are substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkaryl and aralkyl, the hydrocarbon chains of which having from 1 to about 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R 1 having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R 1 being sufficient to impart a membrane binding stability of at least 30% to said compound; R 2 represents a spacer moiety of the formula: --(R 3 ) p --Q--(R 4 --Q') q --(R 5 --Q"),--(R 6 --Q"') a --(R 7 Q"").sub.τ -- wherein R 3 represents an aliphatic hydrocarbon, R 4 , R 5 , R 6 and R 7 are independently selected from the group consisting of aliphatic, alicyclic or aromatic hydrocarbons, heterocycles, and CH 2 C(CO 2 M)=CH, Q and Q', Q", Q"' and Q"" are independently selected from the group of functional linkages consisting of amide, thiourea, hydrazone, acyl hydrazone, ketal, acetal, orthoester, ester, anhydride, disulfide, urea, carbamate, imine, amine, ether, carbonate, thioether, sulfonamide carbonyl and amidine linkages; Q', Q", Q"', Q"" may additionally independently represent a valence bond; said aliphatic hydrocarbons having from 1 to 12 linear carbon atoms; said aromatic hydrocarbons having from 6 to 12 carbon atoms; n, p, q, r, s, and t each may be either 0 or 1; X and X 1 may be the same or different and represent O, S, C(CH 3 ) 2 or Se; R 8 is independently selected from the group consisting of H, CE 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ; y may be from 0 to 3; Z represents a substituent selected from the group consisting of H, alkyl, OH, --O--alkyl, COOH, CONH 2 , SO 3 H, SO 2 NH 2 , SH, S-alkyl, CONH-alkyl, CON-(alkyl) 2 , NH-acyl, NH-alkyl, N(alkyl) 2 , NO 2 , halogen, Si(alkyl) 3 , O-Si(alkyl) 3 , Sn(alkyl) 3 and --Hg--halogen, the alkyl groups comprising said Z substituent having from 1 to 4 carbon and A represents a pharmaceutically acceptable anion.
Claim 2
Dependent Claim 384 words
A compound having the formula: wherein B represents a chemotherapeutic substance; R and R 1 are substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkaryl and aralkyl, the hydrocarbon chains of which having from 1 to about 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R 1 having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R 1 being sufficient to impart a membrane binding stability of at least 30% to said compound; R 2 represents a spacer moiety of the formula: --(R 3 ) p --Q--(R 4 --Q') q --(R 5 --Q"),--(R 6 --Q"') a --(R 7 Q"").sub.τ -- wherein R 3 represents an aliphatic hydrocarbon, R 4 , R 5 , R 6 and R 7 are independently selected from the group consisting of aliphatic, alicyclic or aromatic hydrocarbons, heterocycles, and CH 2 C(CO 2 M)=CH, Q and Q', Q", Q"' and Q"" are independently selected from the group of functional linkages consisting of amide, thiourea, hydrazone, acyl hydrazone, ketal, acetal, orthoester, ester, anhydride, disulfide, urea, carbamate, imine, amine, ether, carbonate, thioether, sulfonamide carbonyl and amidine linkages; Q', Q", Q"', Q"" may additionally independently represent a valence bond; said aliphatic hydrocarbons having from 1 to 12 linear carbon atoms; said aromatic hydrocarbons having from 6 to 12 carbon atoms; n, p, q, r, s, and t each may be either 0 or 1; X and X 1 may be the same or different and represent O, S, C(CH 3 ) 2 or Se; R 8 is independently selected from the group consisting of H, CE 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 and CH(CH 3 ) 2 ; y may be from 0 to 3; Z represents a substituent selected from the group consisting of H, alkyl, OH, --O--alkyl, COOH, CONH 2 , SO 3 H, SO 2 NH 2 , SH, S-alkyl, CONH-alkyl, CON-(alkyl) 2 , NH-acyl, NH-alkyl, N(alkyl) 2 , NO 2 , halogen, Si(alkyl) 3 , O-Si(alkyl) 3 , Sn(alkyl) 3 and --Hg--halogen, the alkyl groups comprising said Z substituent having from 1 to 4 carbon and A represents a pharmaceutically acceptable anion.
Claim 3
Dependent Claim 27 words
A compound as claimed in claim 1, comprising a radioisotope selected from the group consisting of radioactive hydrogen, carbon, nitrogen, halogen, sulphur, selenium or a combination thereof.
Claim 4
Dependent Claim 27 words
A compound as claimed in claim 1, wherein said chemotherapeutic substance is selected from the group consisting of immunogens, toxins, hormones, enzymes, antigens, antibodies and antibody fragments.
Claim 5
Dependent Claim 11 words
A compound, according to claim 1 of the formula: ##STR18## .
Claim 6
Dependent Claim 11 words
A compound, according to claim 1, of the formula: ##STR19## .
Claim 7
Dependent Claim 11 words
A compound, according to claim 1, of the formula: ##STR20## .
Claim 8
Dependent Claim 15 words
A compound as claimed in claim 1, wherein said chemotherapeutic substance comprises a nucleic acid.
Claim 9
Dependent Claim 15 words
A compound as claimed in claim 1, wherein said chemotherapeutic agent comprises an anitproliferative agent.
Claim 10
Dependent Claim 25 words
A compound as claimed in claim 8, wherein said antiproliferative agent is selected from the group consisting of colchicine, vinca alkaloids, taxol and derivatives thereof.
Claim 11
Dependent Claim 14 words
A compound as claimed in claim 8, wherein said chemotherapeutic substance comprises an anticoagulant.
Claim 12
Dependent Claim 23 words
A compound as claimed in claim 10, wherein said anticoagulant is selected from the group consisting of heparin, heparin fragments and heparin derivatives.
Claim 13
Dependent Claim 21 words
A compound as claimed in claim 10, wherein said anticoagulant is selected from the group consisting of hirudin and hirudin derivatives.

References Cited (Backward Citations)

US2647054A Cited
US4427649A Cited
US4473652A Cited
US4471113A Cited
US4501728A Cited
US4867973A Cited
US4689292A Cited
US4751219A Cited
US4762701A Cited
US4783401A Cited
US4859584A Cited
US4906749A Cited
US5132290A Cited
WO1989010758A1 Cited
EP0353450A1 Cited
US5223263A Cited
WO1990003401A1 Cited
US5194654A Cited
WO1991016024A1 Cited
WO1991017424A1 Cited
US5149794A Cited
US5246951A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-09-15 2001-03-17 2001-09-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-09-15 2005-03-17 2005-09-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-09-15 2009-03-17 2009-09-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag